+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acromegaly - Pipeline Review, H2 2018

  • ID: 4622994
  • Drug Pipelines
  • 89 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Aegis Therapeutics LLC
  • Amryt Pharma plc
  • Camurus AB
  • Chiasma Inc
  • DexTech Medical AB
  • Ionis Pharmaceuticals Inc
  • MORE
Acromegaly - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H2 2018, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.

Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.

Report Highlights:

This latest pipeline guide Acromegaly - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 5, 7 and 3 respectively.

Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aegis Therapeutics LLC
  • Amryt Pharma plc
  • Camurus AB
  • Chiasma Inc
  • DexTech Medical AB
  • Ionis Pharmaceuticals Inc
  • MORE
Introduction

Report Coverage

Acromegaly - Overview

Acromegaly - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Acromegaly - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acromegaly - Companies Involved in Therapeutics Development

Aegis Therapeutics LLC

Amryt Pharma plc

Antisense Therapeutics Ltd

Aquestive Therapeutics Inc

Auritec Pharmaceuticals Inc

Camurus AB

Chiasma Inc

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Dauntless Pharmaceuticals Inc

DexTech Medical AB

GeneScience Pharmaceuticals Co Ltd

Ionis Pharmaceuticals Inc

Italfarmaco SpA

leon-nanodrugs GmbH

Midatech Pharma Plc

Ono Pharmaceutical Co Ltd

Strongbridge Biopharma plc

Sun Pharma Advanced Research Company Ltd

Acromegaly - Drug Profiles

AP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atesidorsen sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRN-00808 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-GHRLRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ITF-2984 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanreotide SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leon-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate microspheres - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide LA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-5788 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Somadex - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide MR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acromegaly - Dormant Projects

Acromegaly - Discontinued Products

Acromegaly - Product Development Milestones

Featured News & Press Releases

Sep 13, 2018: Chiasma Announces Poster Presentation at the 9th International Congress of the Growth Hormone Research and IGF Societies

Aug 31, 2018: Midatech announces interim results from proof of concept exploratory study for its MTD201 Q-Octreotide programme and Q-Sphera microsphere technology

Jul 27, 2018: Chiasma ends enrolment in MPOWERED trial for acromegaly

Jun 21, 2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Acromegaly

Jun 18, 2018: Chiasma to Present on New Methodologies in Acromegaly Clinical Trial Design at 12th Acromegaly Consensus Conference

Jun 14, 2018: ATL1103/atesidorsen Early Access Program - Progress Update

Jun 14, 2018: Chiasma Achieves 50% of Target Patients Randomized in CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly

May 23, 2018: ATL1103 Phase II Trial Results Published in the European Journal of Endocrinology

May 21, 2018: Midatech commences equivalence study in exploratory phase of Q-Octreotide (MTD201) for carcinoid cancer and acromegaly

May 14, 2018: Chiasma Announces FDA Agreement to Redefine Certain Secondary Endpoints in CHIASMA OPTIMAL Phase 3 Clinical Trial

May 10, 2018: Chiasma Reports First Quarter 2018 Results

Mar 16, 2018: Chiasma Announces Poster Presentation at ENDO 2018 on Study Design of Phase 3 Double-Blind Trial Evaluating Oral Octreotide Capsules Versus Placebo in Patients with Acromegaly

Mar 12, 2018: Crinetics Pharmaceuticals Announces Upcoming Presentation on Acromegaly Drug Candiadate CRN00808 at ENDO 2018

Feb 28, 2018: ATL1103/atesidorsen Early Access Program - Update

Jan 30, 2018: FDA Grants Orphan Drug Designation to Dauntless Pharmaceuticals DP1038 for the Treatment of Acromegaly

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Acromegaly, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Acromegaly - Pipeline by Aegis Therapeutics LLC, H2 2018

Acromegaly - Pipeline by Amryt Pharma plc, H2 2018

Acromegaly - Pipeline by Antisense Therapeutics Ltd, H2 2018

Acromegaly - Pipeline by Aquestive Therapeutics Inc, H2 2018

Acromegaly - Pipeline by Auritec Pharmaceuticals Inc, H2 2018

Acromegaly - Pipeline by Camurus AB, H2 2018

Acromegaly - Pipeline by Chiasma Inc, H2 2018

Acromegaly - Pipeline by Crinetics Pharmaceuticals Inc, H2 2018

Acromegaly - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018

Acromegaly - Pipeline by Dauntless Pharmaceuticals Inc, H2 2018

Acromegaly - Pipeline by DexTech Medical AB, H2 2018

Acromegaly - Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2018

Acromegaly - Pipeline by Ionis Pharmaceuticals Inc, H2 2018

Acromegaly - Pipeline by Italfarmaco SpA, H2 2018

Acromegaly - Pipeline by leon-nanodrugs GmbH, H2 2018

Acromegaly - Pipeline by Midatech Pharma Plc, H2 2018

Acromegaly - Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

Acromegaly - Pipeline by Strongbridge Biopharma plc, H2 2018

Acromegaly - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018

Acromegaly - Dormant Projects, H2 2018

Acromegaly - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Acromegaly, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aegis Therapeutics LLC
  • Amryt Pharma plc
  • Antisense Therapeutics Ltd
  • Aquestive Therapeutics Inc
  • Auritec Pharmaceuticals Inc
  • Camurus AB
  • Chiasma Inc
  • Crinetics Pharmaceuticals Inc
  • Daewoong Pharmaceutical Co Ltd
  • Dauntless Pharmaceuticals Inc
  • DexTech Medical AB
  • GeneScience Pharmaceuticals Co Ltd
  • Ionis Pharmaceuticals Inc
  • Italfarmaco SpA
  • leon-nanodrugs GmbH
  • Midatech Pharma Plc
  • Ono Pharmaceutical Co Ltd
  • Strongbridge Biopharma plc
  • Sun Pharma Advanced Research Company Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4622994
Adroll
adroll